PAM
NBIX icon

Princeton Alpha Management’s Neurocrine Biosciences NBIX Stock Holding History

Princeton Alpha Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-5,368
Closed -$214K – 855
2015
Q3 		$214K Sell
5,368
-3,257
-38% -$157K 0.04% 586
2015
Q2 		$412K Sell
8,625
-1,630
-16% -$69.1K 0.08% 359
2015
Q1 		$407K Buy
+10,255
New +$367K 0.09% 327

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Princeton Alpha Management's NBIX Position: Q4 2015 in Review

Princeton Alpha Management sold out of Neurocrine Biosciences (NBIX) in Q4 2015, closing a stake of 5,368 shares — an estimated $214K sold.

Princeton Alpha Management first reported a position in NBIX in Q1 2015 and held it in 3 quarters. The position peaked at $412K in Q2 2015. 218 funds tracked by Wall St. Rank hold NBIX as of Q4 2015.

  • Princeton Alpha Management reported no remaining Neurocrine Biosciences position as of Q4 2015 after selling out during the quarter.
  • Princeton Alpha Management sold 5,368 Neurocrine Biosciences shares in Q4 2015, an estimated $214K.
  • Princeton Alpha Management first reported a position in Neurocrine Biosciences in Q1 2015 and held it in 3 quarters.
  • Princeton Alpha Management's Neurocrine Biosciences position peaked at $412K in Q2 2015.
  • 218 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2015.

Based on Princeton Alpha Management's 13F filing for Q4 2015, filed 4 Feb 2016.